{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:10:13Z","timestamp":1778591413368,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN-152254"],"award-info":[{"award-number":["FRN-152254"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-143328"],"award-info":[{"award-number":["FDN-143328"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.urolonc.2020.04.028","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T20:20:23Z","timestamp":1594326023000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Androgen deprivation therapy for prostate cancer and the risk of bladder cancer: A systematic review of observational studies"],"prefix":"10.1016","volume":"38","author":[{"given":"Christina","family":"Santella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Rouette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Brundage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.urolonc.2020.04.028_bib0001","doi-asserted-by":"crossref","first-page":"14710","DOI":"10.18632\/oncotarget.3817","article-title":"Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy","volume":"6","author":"Shiota","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.028_bib0002","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.028_bib0003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers9020020","article-title":"Androgen receptor signaling in bladder cancer","volume":"9","author":"Li","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2020.04.028_bib0004","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3892\/mco.2017.1389","article-title":"Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.04.028_bib0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/jnci\/djk113","article-title":"Promotion of bladder cancer development and progression by androgen receptor signals","volume":"99","author":"Miyamoto","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.urolonc.2020.04.028_bib0006","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1530\/ERC-15-0209","article-title":"The emerging role of the androgen receptor in bladder cancer","volume":"22","author":"Lombard","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174746","article-title":"Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies","volume":"12","author":"Ide","year":"2017","journal-title":"PLoS One"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2020.04.028_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.471","article-title":"Results from a phase I\/Ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer (mBC)","volume":"37","author":"Gupta","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0009","series-title":"Enzalutamide for Bladder Cancer Chemoprevention","author":"Messing","year":"2017"},{"issue":"7","key":"10.1016\/j.urolonc.2020.04.028_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/thoraxjnl-2016-209512","article-title":"Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia","volume":"72","author":"Hicks","year":"2017","journal-title":"Thorax"},{"issue":"Suppl 5","key":"10.1016\/j.urolonc.2020.04.028_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bju.12964","article-title":"Adverse effects of androgen-deprivation therapy in prostate cancer and their management","volume":"115","author":"Rhee","year":"2015","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2020.04.028_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0013","unstructured":"Sterne JAC RB. The ROBINS-I Tool (Risk of Bias in Non-Randomized Studies of Interventions)2016[Available from:https:\/\/sites.google.com\/site\/riskofbiastool\/."},{"key":"10.1016\/j.urolonc.2020.04.028_bib0014","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2337\/dc15-1816","article-title":"Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies","volume":"39","author":"Wu","year":"2016","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.urolonc.2020.04.028_bib0016","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.urolonc.2020.04.028_bib0017","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0018","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.urolonc.2020.04.028_bib0019","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.028_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/EDE.0b013e3182093a0f","article-title":"Time-window bias in case-control studies: statins and lung cancer","volume":"22","author":"Suissa","year":"2011","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0021","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"10.1016\/j.urolonc.2020.04.028_bib0022","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.2011.822","article-title":"Surveillance bias in outcomes reporting","volume":"305","author":"Haut","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.urolonc.2020.04.028_bib0023","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bcp.12705","article-title":"Indication bias or protopathic bias?","volume":"80","author":"Faillie","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0024","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2009.09076.x","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2020.04.028_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/030089160709300102","article-title":"Risk factors for bladder cancer","volume":"93","author":"Jankovic","year":"2007","journal-title":"Tumori"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0026","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bjc.2017.280","article-title":"Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study","volume":"117","author":"Haque","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0027","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/CMAR.S185867","article-title":"High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.04.028_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/tau.2019.01.15","article-title":"Prediction tools in non-muscle invasive bladder cancer","volume":"8","author":"Zamboni","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.028_bib0029","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0030","first-page":"108","article-title":"Bladder cancer after radiotherapy for prostate cancer","volume":"15","author":"Suriano","year":"2013","journal-title":"Rev Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.04.028_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102596","article-title":"Incidence of second malignancies for prostate cancer","volume":"9","author":"Van Hemelrijck","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.028_bib0032","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1158\/1055-9965.EPI-12-1137","article-title":"Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies","volume":"22","author":"Wallner","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.urolonc.2020.04.028_bib0033","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00345-018-2504-3","article-title":"The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer","volume":"37","author":"Moschini","year":"2019","journal-title":"World J Urol"},{"issue":"24","key":"10.1016\/j.urolonc.2020.04.028_bib0034","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.18632\/oncotarget.2851","article-title":"Androgen deprivation therapy prevents bladder cancer recurrence","volume":"5","author":"Izumi","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2020.04.028_bib0035","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","article-title":"Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-Reductase inhibitor","volume":"197","author":"Shiota","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0036","article-title":"Androgen suppression therapy is associated with lower recurrence of non-muscle-invasive bladder cancer","author":"Wu","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.urolonc.2020.04.028_bib0037","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/ijms20040821","article-title":"Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles","volume":"20","author":"Oeyen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0038","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/14728222.2017.1280468","article-title":"Androgen receptor activation: a prospective therapeutic target for bladder cancer?","volume":"21","author":"Mizushima","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.urolonc.2020.04.028_bib0039","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.juro.2008.07.038","article-title":"Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study","volume":"180","author":"Nieder","year":"2008","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.04.028_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1756287210374462","article-title":"Secondary malignancies following radiotherapy for prostate cancer","volume":"2","author":"Sountoulides","year":"2010","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urolonc.2020.04.028_bib0041","unstructured":"PRISMA. PRISMA: transparent reporting of systematic reviews and meta-analyses 2015. Available from: http:\/\/www.prisma-statement.org\/."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920301836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920301836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:22:26Z","timestamp":1778588546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920301836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1078143920301836"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen deprivation therapy for prostate cancer and the risk of bladder cancer: A systematic review of observational studies","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}